Kidney Damage in Patients With Normal eGFR
| Status: | Archived |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2010 |
| End Date: | June 2011 |
A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated
contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled
must have normal eGFR. Statistical summaries will be presented to analyse the various
laboratory tests for the two groups.
We found this trial at
1
site
Click here to add this to my saved trials
